DARLING INGREDIENTS INC.
DAR
$60.02
-1.88%
Darling Ingredients Inc. is a global developer and producer of sustainable natural ingredients derived from edible and inedible bio-nutrients, processing by-products of the animal agriculture and food industries into collagen (gelatin and hydrolyzed collagen), animal feed, pet food ingredients, biofuels, and renewable energy products across the pharmaceutical, food, industrial, and bioenergy end markets. As the world's largest renderer and a vertically integrated platform spanning Feed Ingredients, Food Ingredients, and Fuel Ingredients, the company occupies a unique position at the intersection of the circular economy, protein nutrition, and renewable fuels — a niche that is difficult to replicate given its scale, global facility footprint, and 15,000-employee operating base. The current investor narrative centers on a dramatic earnings inflection: after a multi-quarter trough driven by weak collagen demand, fat-price compression, and renewable fuel margin volatility, Darling has posted a sharp sequential and year-over-year profit rebound, with Q2 2026 net income of $387 million and EPS of $2.44 dwarfing the year-ago $0.08. That recovery, combined with a strong-buy consensus and a forward P/E below 10x, has made DAR a favored value-recovery and margin-normalization story, though debate persists over the durability of fuel-segment margins and the sustainability of the collagen rebound.…
DAR
DARLING INGREDIENTS INC.
$60.02
Related headlines
Investment Opinion: Should I buy DAR Today?
The synthesized recommendation is Buy, with a thesis that Darling Ingredients is a deeply undervalued earnings-recovery story trading at less than 10x forward earnings while analysts see 29.6% upside to their average target of $81.58. The strong-buy consensus (1.25 mean rating from 12 analysts) and the dramatic Q2 2026 earnings beat (EPS of $2.44 vs. $0.08 year-ago) provide compelling evidence that the company has turned the corner. However, the Buy rating is contingent on the sustainability of recent margin gains, and investors should size positions accordingly given the volatility.
Supporting evidence includes: (1) forward P/E of 9.95x versus a trailing P/E of 94.1x, indicating the market expects a massive earnings ramp that has already begun; (2) revenue growth of 16.5% year-over-year in Q2 2026, with gross margin expanding to 46.9% from 15.1%; (3) TTM free cash flow of $881 million, providing ample liquidity for debt reduction or reinvestment; and (4) a price-to-sales ratio of 0.97 and EV/EBITDA of 12.7x, which are reasonable for a company with Darling's scale and market position. The average analyst target of $81.58 implies a 29.6% upside, and even the low target of $65 is above the current price.
The biggest risks that could invalidate this thesis are: (1) a sharp reversal in fuel segment margins if biofuel credit prices or fat prices decline; (2) a slowdown in collagen demand that would undermine the food ingredients recovery; and (3) the company's high leverage (debt-to-equity 0.88) and interest burden ($163.8 million in Q2) limiting financial flexibility. The rating would upgrade to a high-conviction Buy if the company demonstrates two consecutive quarters of gross margin above 40%, and would downgrade to Hold if gross margin falls below 25% or if forward EPS estimates are revised down by more than 20%. Relative to its own history and peers, DAR appears undervalued on forward earnings, but the market is clearly pricing in execution risk.
Sign up to view all
DAR 12-Month Price Forecast
The forward-looking view is bullish, supported by the dramatic earnings inflection, deeply discounted forward valuation, and unanimous analyst optimism. However, confidence is medium rather than high because the sustainability of Q2's extraordinary margins is unproven, and the stock's recent underperformance (-6.9% over one month) suggests the market is skeptical. The key risk is that forward EPS estimates of $5.15 prove too optimistic if fuel margins normalize and collagen demand slows. I would upgrade to high confidence if the company reports a second consecutive quarter of gross margin above 40% and raises guidance. I would downgrade to neutral if gross margin falls below 25% or if forward EPS estimates are cut by more than 15%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on DARLING INGREDIENTS INC.'s 12-month outlook, with a consensus price target around $81.58 and implied upside of +35.9% versus the current price.
Average Target
$81.58
0 analysts
Implied Upside
+35.9%
vs. current price
Analyst Count
—
covering this stock
Price Range
$65 - $90
Analyst target range
Drowning in data?
Find the real signal!
Bulls vs Bears: DAR Investment Factors
The bull case currently has stronger evidence, anchored by a dramatic earnings inflection (Q2 EPS of $2.44 vs. $0.08), a forward P/E below 10x, and unanimous analyst support with a $81.58 average target. However, the bear case is not without merit: trailing profitability remains thin (1.02% net margin), the fuel segment's margin durability is unproven, and recent price weakness (-6.9% over one month) suggests the market is skeptical of the recovery's sustainability. The single most important tension is whether the Q2 margin surge — particularly the 46.9% gross margin — represents a new normal or a cyclical peak. If margins hold, the stock is deeply undervalued; if they revert, the forward earnings estimates that justify the low P/E will prove illusory.
Bullish
- Earnings inflection is dramatic: Q2 2026 EPS of $2.44 versus $0.08 in the year-ago quarter represents a 30x increase, with net income of $387 million versus $12.7 million. This is not a modest recovery but a step-change in profitability that validates the margin-normalization thesis.
- Forward P/E below 10x is deeply discounted: With a forward P/E of 9.95x and trailing P/E of 94.1x, the market is pricing in a massive earnings recovery that has already begun. Analyst EPS estimates average $5.15 for the forward year, implying the stock trades at less than 10x forward earnings — a steep discount to the broader market.
- Analyst consensus is overwhelmingly bullish: 12 analysts rate DAR a strong buy (recommendation mean 1.25) with an average target price of $81.58, implying 29.6% upside from the current $62.94. Even the lowest target of $65 sits above the current price, suggesting a favorable risk/reward skew.
- Revenue growth accelerating with margin expansion: Q2 2026 revenue grew 16.5% year-over-year to $1.72 billion, while gross margin expanded to 46.9% from 15.1% in the year-ago quarter. This combination of top-line growth and dramatic margin improvement signals operating leverage and pricing power.
Bearish
- Trailing profitability remains weak: Despite the Q2 surge, trailing net margin is just 1.02% and ROE is 1.33%, reflecting the deep earnings trough of prior quarters. The trailing P/E of 94.1x underscores how much of the recovery is still ahead rather than already delivered.
- Fuel segment margin durability is uncertain: The renewable fuel segment is exposed to volatile fat prices and biofuel credit markets, which have historically caused earnings swings. The Q2 EBITDA margin of 39.6% may not be sustainable if fuel margins normalize, as they did in prior cycles.
- Recent price momentum has turned negative: DAR has declined 6.9% over the past month and 2.6% over six months, underperforming the S&P 500 by 7.5 and 20.0 percentage points respectively. This relative weakness suggests the market is questioning the sustainability of the earnings rebound.
- High leverage relative to earnings volatility: Interest expense of $163.8 million in Q2 alone consumes a significant portion of operating income, and debt-to-equity of 0.88 leaves limited cushion if earnings decline. The company's beta of 1.03 offers no defensive offset during market downturns.
DAR Technical Analysis
Beta
1.05
1.05x market volatility
Max Drawdown
-19.0%
Largest decline past year
52-Week Range
$29-$70
Price range past year
Annual Return
+94.1%
Cumulative gain past year
| Period | DAR Return | S&P 500 |
|---|---|---|
| 1m | -7.9% | +0.9% |
| 3m | -0.3% | +3.4% |
| 6m | -2.0% | +14.4% |
| 1y | +94.1% | +16.2% |
| ytd | +59.5% | +14.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
DAR Fundamental Analysis
Quarterly Revenue
$1.7B
2026-07
Revenue YoY Growth
+16.5%
YoY Comparison
Gross Margin
46.9%
Latest Quarter
Free Cash Flow
$881242000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is DAR Overvalued?
PE
94.1x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 6x~26x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
12.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on the sustainability of Darling's margin recovery and its leverage profile. The company's Q2 2026 gross margin of 46.9% is a dramatic outlier versus the 15.1% reported in the year-ago quarter and the 17.7% in Q1 2026, raising the question of whether this is a structural improvement or a one-time spike. Interest expense of $163.8 million in Q2 consumes roughly 25% of operating income, and with debt-to-equity at 0.88, the company has limited flexibility if earnings revert. Additionally, the collagen and fuel segments are subject to commodity price swings, and the company's trailing net margin of just 1.02% demonstrates how quickly profitability can evaporate.
Market and competitive risks include valuation compression if the earnings recovery stalls, as well as exposure to volatile biofuel and agricultural commodity markets. DAR's beta of 1.03 means it moves roughly in line with the broader market, offering little downside protection. The stock has underperformed the S&P 500 by 20.0 percentage points over the past six months, and its 1-month relative strength of -7.5 suggests negative momentum. Competitive pressures in the rendering and renewable fuel space are intensifying, and any regulatory changes to biofuel mandates or trade policies could disproportionately impact Darling's fuel segment. Recent news flow around food industry headwinds (e.g., Post Holdings' retail volume declines) highlights broader sector challenges.
In a worst-case scenario, a sharp decline in fat prices and renewable fuel margins, combined with a stall in collagen demand, could cause earnings to revert toward the prior trough. If forward EPS estimates of $5.15 prove overly optimistic and actual EPS falls back toward $1–2, the stock could retest its 52-week low of $29.15, representing a 53.7% decline from the current $62.94. Even a moderate disappointment — say, EPS of $3.50 — could push the stock toward the analyst low target of $65, though that would still be above the current price. A more realistic bear case might see the stock fall to the $45–50 range, a 20–28% decline, if fuel margins normalize and collagen growth slows.
FAQ
The most severe risk is the sustainability of fuel segment margins, which drove the Q2 2026 earnings surge. If biofuel credit prices or fat prices decline, gross margin could revert from 46.9% toward the 15–20% range, causing a sharp earnings miss. Second, the company carries significant debt (debt-to-equity of 0.88) with $163.8 million in quarterly interest expense, leaving limited cushion if earnings decline. Third, collagen demand is cyclical and could weaken if global economic growth slows, particularly in key markets like China. Fourth, the stock has a beta of 1.03 and has underperformed the S&P 500 by 20 percentage points over six months, indicating vulnerability to market downturns and sector rotation. Ranked by severity: fuel margin risk is highest, followed by leverage, collagen demand, and macro sensitivity.
The 12-month forecast is based on three scenarios. The base case (50% probability) targets $75–85, assuming forward EPS of $5.15 is achieved and the stock trades up to the analyst average of $81.58. The bull case (30% probability) targets $85–90, driven by sustained gross margins above 40% and EPS exceeding $5.50. The bear case (20% probability) targets $45–55, if fuel margins normalize and EPS estimates are cut to $3.00–$3.50. The most likely scenario is the base case, which assumes the company delivers on consensus expectations without a major macro or commodity shock. The key assumption behind this forecast is that gross margins stabilize in the 30–35% range, above the prior trough but below the Q2 peak.
DAR appears undervalued on forward earnings but expensive on trailing metrics. The forward P/E of 9.95x is well below the broader market and the company's own historical average, suggesting the market is pricing in a successful earnings recovery. However, the trailing P/E of 94.1x and price-to-sales of 0.97 reflect the depressed profitability of the prior year. The EV/EBITDA of 12.7x is reasonable for a company with Darling's scale and market position, and the price-to-book of 1.26 is near historical lows. The market is essentially saying it expects forward EPS of $5.15 to be achieved; if that happens, the stock is cheap. If estimates are cut, the valuation could quickly become expensive. Relative to peers in the packaged foods and renewable energy spaces, DAR trades at a discount on forward earnings, but the discount reflects the cyclicality of its earnings.
From a risk/reward perspective, DAR presents a favorable setup for investors who can tolerate volatility. The stock trades at $62.94, with analysts' average target of $81.58 implying 29.6% upside, and even the lowest target of $65 is above the current price. The forward P/E of 9.95x is undemanding if the earnings recovery holds, and the Q2 2026 EPS of $2.44 versus $0.08 year-ago demonstrates significant operating leverage. However, the biggest downside risk is a reversion in fuel segment margins, which could push the stock back toward its 52-week low of $29.15. For investors with a medium-term horizon and a stomach for commodity-driven swings, DAR is a good buy at current levels, but position sizing should reflect the binary nature of the margin debate.
DAR is best suited for a medium-to-long-term investment horizon of at least 12–18 months, given the cyclical nature of its earnings and the time required for the margin recovery to be validated. The stock does not pay a dividend (payout ratio 0%), so returns depend entirely on capital appreciation. Its beta of 1.03 and historical earnings volatility (EPS swinging from -$0.16 to $2.44 in five quarters) make it unsuitable for short-term trading unless one has a strong view on quarterly commodity prices. For long-term investors, the company's unique circular-economy platform and scale provide a durable competitive advantage, but the path to normalized earnings may be bumpy. A minimum holding period of 18–24 months is recommended to ride out potential commodity cycles and allow the collagen and fuel segments to demonstrate sustainable profitability.
